Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rapport Therapeutics, Inc.

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPP
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPP
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPP
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPP
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPP
Rapport Therapeutics Announces Pricing of Initial Public Offering
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Appoints Chief People Officer
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Appoints Chief Financial Officer
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Names Scientific Advisory Board
From Rapport Therapeutics, Inc.
Via Business Wire
Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies
From Rapport Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.